Somewhat Favorable News Coverage Somewhat Unlikely to Impact Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price
News headlines about Karyopharm Therapeutics (NASDAQ:KPTI) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.7136809350661 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors Nasdaq:KPTI (menafn.com)
- Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting (finance.yahoo.com)
- Christopher Brett Primiano Sells 10,000 Shares of Karyopharm Therapeutics Inc (KPTI) Stock (americanbankingnews.com)
- Sharon Shacham Sells 12,500 Shares of Karyopharm Therapeutics Inc (KPTI) Stock (americanbankingnews.com)
Shares of KPTI traded down $0.14 during trading hours on Friday, hitting $18.72. 513,124 shares of the company were exchanged, compared to its average volume of 446,501. The company has a market cap of $1.13 billion, a PE ratio of -6.66 and a beta of 3.72. Karyopharm Therapeutics has a 52 week low of $9.00 and a 52 week high of $21.71.
Several research analysts have weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $27.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, August 7th. Zacks Investment Research lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. BidaskClub lowered Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Robert W. Baird reaffirmed a “buy” rating and issued a $25.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Finally, ValuEngine raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $22.90.
In other news, insider Sharon Shacham sold 12,500 shares of the company’s stock in a transaction dated Monday, July 9th. The stock was sold at an average price of $18.72, for a total transaction of $234,000.00. Following the completion of the sale, the insider now owns 726,010 shares in the company, valued at approximately $13,590,907.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Christopher Brett Primiano sold 10,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $18.90, for a total value of $189,000.00. Following the sale, the executive vice president now owns 7,881 shares of the company’s stock, valued at approximately $148,950.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,056,701 shares of company stock valued at $20,905,401. 13.26% of the stock is currently owned by corporate insiders.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.